Spain: Management Change Francesca Wuttke Appointed New Chief Digital Officer at Almirall

Under her new role, Wuttke will be responsible for developing and executing end-to-end digital strategy which is expected to be a core area for the firm’s success in the near future.

Related Companies

Cohn & Wolfe

Glatt Ingenieurtechnik GmbH

Pörner Ingenieurgesellschaft mbH

Frewitt fabrique de machines SA

Barcelona/Spain – Almirall has recently announced the appointment of Francesca Domenech Wuttke as the new Chief Digital Officer and member of the Management Board of the company. In her new role, Wuttke will report directly to Peter Guenter, Chief Executive Officer, Almirall, and will be responsible for developing and executing end-to-end digital strategy, a key pillar for the future success of the company.

She will lead the ‘Digital Transformation’ department for the firm, define the new digital governance model, develop and prioritise the enterprise wide ‘Digital Project’ portfolio and work closely with all business stakeholders.

During the last few years, Wuttke has led European investments as Managing Director Europe for the Global Health Innovation Fund MSD’s venture capital arm. The fund is exclusively focused on investments in digital health solutions and services and there, she designed the investment thesis to accelerate the digital clinical trial ecosystem, with much success. For example, she invested in a digital clinical trial patient recruitment platform as well as a platform that interrogates electronic medical records for genomic phenotyping, clinical trial applications and Real World Evidence.

Previously, she also worked as Global Director, Commercial Strategy at Novartis and was also co-founder of Asten Bio Pharma Avisors, a healthcare consultancy that supports business development of biopharmaceutical companies interested in investments in biotechnology. During her experience in venture capital, private equity, start-ups, consulting and pharma companies, Wuttke has shown great ability to distill scientific and clinical data into investment opportunities, having prospected and evaluated hundreds of opportunities.

She holds a PhD in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a B.A. in Biology and Society by the Cornell University College of Arts and Sciences.

(ID:45677230)